

Paper No. \_\_\_\_  
Date Filed: Mar. 17, 2017

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

WOCKHARDT BIO AG,  
Petitioner,

v.

JANSSEN ONCOLOGY, INC.,  
Patent Owner.

---

Case IPR2016-01582  
Patent 8,822,438

---

**JANSSEN ONCOLOGY, INC.'S UPDATED EXHIBIT LIST**

Pursuant to 37 C.F.R. § 42.63(e), Patent Owner, Janssen Oncology, Inc.

hereby submits a current list of its exhibits.

<b>Exhibit</b>	<b>Description</b>
JSN 2001	Notice of Termination of Preprocessing of <i>Ex Parte</i> Reexamination Request
JSN 2002	SEALED Reda Dhanorkar Email Chain – Protective Order Material
JSN 2003	SEALED Reda Declaration – Protective Order Material
JSN 2004	Reda Declaration – Redacted
JSN 2005	Reda Dhanokar Email Chain - Redacted
JSN 2006	Standing Protective Order IPR2016-01582
JSN 2007	Redline of Standing Protective Order IPR2016-01582
JSN 2008	Declaration of David T. Pritikin in Support of Motion to Appear <i>Pro Hac Vice</i>
JSN 2009	Declaration of Bindu Donovan in Support of Motion to Appear <i>Pro Hac Vice</i>
JSN 2010	2016/11/10 (DI 239) – Opinion on Markman Patent Claim Construction (DNJ)
JSN 2011	2016/14/10 (DI 240) – Order on Markman Patent Claim Construction

<b>Exhibit</b>	<b>Description</b>
JSN 2012	PM Live Top 50 Pharmaceuticals
JSN 2013	Johnson & Johnson Press Release 1/26/2016
JSN 2014	Johnson & Johnson Press Release 1/24/2017
JSN 2015	Declaration of Dr. Marc Garnick
JSN 2016	Deposition Transcript of Marc B. Garnick, M.D., taken by Patent Owner on February 16, 2017
JSN 2017	Declaration of Scott Serels, MD, filed on Dec. 4, 2015 in <i>Amerigen Pharmaceuticals Ltd. v. Janssen Oncology, Inc.</i> , IPR2016-00286.
JSN 2018	Deposition Transcript of Scott R. Serels, taken by Patent Owner on January 21, 2017 in <i>Amerigen Pharmaceuticals Ltd. v. Janssen Oncology, Inc.</i> , IPR2016-00286.
JSN 2019	Declaration of Scott Serels, MD, filed on Jan. 16, 2017 in <i>Amerigen Pharmaceuticals Ltd. v. Janssen Oncology, Inc.</i> , IPR2016-00286.
JSN 2020	Deposition Transcript of Scott Serels, M.D., taken by Patent Owner on August 22, 2016 in <i>Amerigen Pharmaceuticals Ltd. v. Janssen Oncology, Inc.</i> , IPR2016-00286.

<b>Exhibit</b>	<b>Description</b>
JSN 2021	Boumpas et al., “Glucocorticoid Therapy for Immune-mediated Diseases: Basic and Clinical Correlates,” <i>Ann. Internal Medicine</i> , 119:1198-1208 (1993)
JSN 2022	Debruyne and Witjes, “Ketoconazole High Dose (H.D.) In The Management Of Metastatic Prostatic Carcinoma,” <i>The Journal of Urology</i> , 135(4, pt.2):203A, Abstract 397 (1986)
JSN 2023	Herr and Pfitzenmaier, “Glucocorticoid use in prostate cancer and other solid tumours: implications for effectiveness of cytotoxic treatment and metastases,” <i>The Lancet</i> , 7:425-430 (2006)
JSN 2024	Krishnan et al., “A Glucocorticoid-Responsive Mutant Androgen Receptor Exhibits Unique Ligand Specificity: Therapeutic Implications for Androgen-Independent Prostate Cancer,” <i>Endocrinology</i> , 145:1889-1900 (2002)
JSN 2025	Conde and Aronson, “Risk factors for male osteoporosis,” <i>Urologic Oncology</i> , 21:380-383 (2003)
JSN 2026	Remington – <i>The Science and Practice of Pharmacy</i> , 20 <sup>th</sup> ed., pp. 1363-1370 (2000)

<b>Exhibit</b>	<b>Description</b>
JSN 2027	Rumohr and Chang, "Current chemotherapeutic approaches for androgen-independent prostate cancer," <i>Current Opinion in Investigational Drugs</i> , 7(6):529-533 (2006)
JSN 2028	Declaration of Professor Ian Judson, M.D.
JSN 2029	Judson CV
JSN 2030	Clinical Cancer Research Peer Review letter to Judson, dated May 12, 2003
JSN 2031	Burgess and Roth, "Changing Perspectives of the Role of Chemotherapy in Advanced Prostate Cancer," <i>Urol. Clin. N. Am.</i> , 33:227-236 (2006)
JSN 2032	Strother et al., "Novel cytotoxic and biological agents for prostate cancer: Where will the money be in 2005?," <i>European Journal of Cancer</i> , 41:954-964 (2005)
JSN 2033	Reserved
JSN 2034	Press Release 1/21/2014
JSN 2035	Press Release 1/20/2015
JSN 2036	Hadaschik et al., "Novel targets and approaches in advanced prostate cancer," <i>Current Opinions Urology</i> , 17:182-187 (2007)

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.